RIGL: Rigel Pharmaceuticals, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 4, 12:45 PM Midday top 10 gainers: ET +53%. NURO +47%. INFI +20%. GIII +18%. OIBR +18%. IFMI +12%. MHGC +13%. WPCS +13%. BEAT +12%. AMPE +12%. Midday top 10 Losers: FBN -19%. RIGL -18%. LPHI -13%. PSTI -14%. GIG -10%. BTX -10%. OSH -10%. VRML -10%. ENTA -9%. ZLC -10%. Comment!
Tuesday, June 4, 9:11 AM Premarket gainers: ET +53%. MHGC +18%. INFI +9%. MFG +9%. MKTG +9%. SMFG +8%. NMR +8%. MTU +7%. FCEL +6%. MCHP +5%.
Losers: RIGL -23%. DG -7%. SLCA -6%. Comment! [On the Move]
Tuesday, June 4, 6:01 AM AstraZeneca (AZN) is ending the development of rheumatoid arthritis pill Fostamatinib following mixed results in Phase II and III trials, including in comparison with Abbott's (ABT) Humira. AstraZeneca will take a charge of $140M on its Q2 results and return the rights to Fostamatinib to U.S. partner Rigel Pharmaceuticals (RIGL), whose shares are -6.8%. AstraZeneca's are -0.2%. Comment! [Healthcare]
Wednesday, May 22, 10:37 AM Rigel Pharmaceuticals (RIGL +0.4%) says it's made clinical advancement in three programs currently in development. The first program is R348, a topical ophthalmic formulation of a JAK/SYK inhibitor being developed to treat dry eye disease. The company notes that the drug was well tolerated in Phase 1 trials, and it plans to initiate Phase 2 trials soon. The other two are oncology programs being conducted by corporate partners, including an AXL kinase inhibitor under development by BerGenBio AS and a ligase inhibitor by Daiichi Sankyo (DSNKY.PK). Comment! [Healthcare, Global & FX]
Tuesday, May 7, 12:38 PM Rigel Pharmaceuticals (RIGL -2.7%) slips after reporting an in-line Q1, but losses were higher Y/Y due to an absence of contract revenue and higher operating costs. Total operating expenses were $25.7M for the quarter, compared to $24.1M in Q112. The increase was primarily due to R&D expense related to ongoing studies of R348, its topical ophthalmic JAK/SYK inhibitor program for chronic dry eye, and R343, an inhaled SYK inhibitor program for asthma. Comment! [Healthcare, On the Move, Earnings]
Tuesday, May 7, 7:45 AM Rigel Pharmaceuticals (RIGL): Q1 EPS of -$0.29 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Friday, April 5, 5:38 PM After-hours top gainers, as of 5:15 p.m.: GOL +6%. PSUN +6%. MEET +3.5%. RIGL +3.3%. CIA +2.5%.
After-hours top losers: HNR -7.6%. BTH -6.3%. SYRG -6%. MM -5.7%. EVC -4.5%. Comment! [On the Move]
Friday, April 5, 9:10 AM Premarket gainers: XIDE +31%. NIHD +10%. NVAX +5%.
Losers: RIGL -36%. FFIV -18%. RDWR -18%. JNPR -7%. CBMX -5%. Comment! [On the Move]
Friday, April 5, 8:58 AM Rigel Pharmaceuticals (RIGL) plummets before the bell after adverse side effects were observed in a late-stage clinical trial of AstraZeneca's (AZN) rheumatoid arthritis drug fostamatinib. It also appears the drug may be inferior to AbbVie's Humira in terms of efficacy. The drug is licensed from Rigel whose shares are -35% premarket on heavy volume. Comment! [Healthcare, On the Move]
Thursday, March 7, 5:54 PM After-hours top gainers, as of 5:15 p.m.: P +19%. AMBA +9%. PETS +7%. PANL +6%. RIGL +5%.
After-hours top losers: MED -9%. ZQK -9%. AVG -6%. SKUL -6%. ANGO -5%. 1 Comment [On the Move]
Tuesday, March 5, 2:27 PM Rigel Pharmaceuticals (RIGL +5.4%) moves up today with a solid Q4 earnings beat on narrower losses. Piper Jaffray notes that the company's key drug fostamatinib's Phase 3 studies look encouraging, and will provide an upside to stock performance over the near term. JP Morgan agrees, saying that rheumatoid arthritis represents a huge and growing worldwide annual market of nearly $13B, and fostamatinib could emerge as a meaningful player in this space. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 5, 7:38 AM Rigel Pharmaceuticals (RIGL): Q4 EPS of -$0.30 beats by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, December 14, 2012, 12:45 PM Midday top 10 gainers: ALIM +30%. STXS +19%. QUAD +18%. RIGL +15%. CHOP +19%. OTT +16%. ZAZA +13%. ALU +12%. AXR +11%. SZYM +11%.
Midday top 10 Losers: YOD -23%. LPTN -18%. CYTX -15%. ZQK -15%. BBY -15%. USNA -11%. PAY -10%. MEIP -9%. LAS -9%. VGZ -10%. Comment!
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]

RIGL Rigel Pharmaceuticals, Inc.

RIGL

Rigel Pharmaceuticals, Inc.